Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Loading...
Community
/
Germany
/
Pharmaceuticals & Biotech
/
Sartorius
Create a narrative
Sartorius Community
XTRA:SRT3 Community
3
Narratives
written by author
0
Comments
on narratives written by author
12
Fair Values set
on narratives written by author
Community Investing Ideas
Sartorius
Popular
Undervalued
Overvalued
Sartorius
AN
AnalystHighTarget
Community Contributor
Cell And Gene Therapies Will Expand Secular Bioproduction
Key Takeaways Expanding innovation in bioprocessing and preclinical services positions Sartorius to capture outsized growth from next-generation therapies and the shift from animal testing. Strong recurring revenue, rising emerging market presence, and operational leverage signal sustained earnings and margin gains beyond current market expectations.
View narrative
€310
FV
32.3% undervalued
intrinsic discount
10.89%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
13 days ago
author updated this narrative
Sartorius
AN
AnalystConsensusTarget
Based on Analyst Price Targets
Advanced Biologic Adoption Will Expand Global Reach
Key Takeaways Strong product innovation and rising demand for advanced biologic drugs are strengthening Sartorius' recurring revenues, margins, and competitive position. Expanding global healthcare access and consumables growth diversify revenue streams and reduce cyclicality, supporting sustained and higher-quality earnings.
View narrative
€260.05
FV
19.2% undervalued
intrinsic discount
9.16%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
7
users have followed this narrative
20 days ago
author updated this narrative
Sartorius
AN
AnalystLowTarget
Community Contributor
Rising Tariffs, Regulatory Hurdles And Cost Pressures Will Squeeze Margins
Key Takeaways Rising protectionism, regulatory changes, and industry consolidation threaten Sartorius' revenue growth, margins, and market reach through suppressed pricing power and supply chain fragmentation. Technological disruption and intensifying lower-cost competition risk obsolescence of core products, pressuring innovation, margin expansion, and returns on research investments.
View narrative
€191.2
FV
9.8% overvalued
intrinsic discount
6.64%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
2 months ago
author updated this narrative